Resverlogix Corp.

Resverlogix Corp.

RVXCF - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$15.83M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Resverlogix Corp.Resverlogix Corp.-1.5-11%--0.8

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$15.83 Million
Enterprise Value$93.13 Million
Earnings per Share$-0.03
Beta1.06
Outstanding Shares329,206,258

Return

Return on Equity10.89%ROE
Return on Assets-121.27%
Return on Invested Capital14.67%

Valuation & Multiples

P/E Ratio-1.52P/E Ratio
PEG3.75PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.05Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-16.11
Enterprise Value to Net Income-10
Total Debt to Enterprise0.83
Debt to Equity-0.82Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 16, 2026
EPS
-$0.00
Reported
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Resverlogix Corp.

19 employees
CEO: Donald J. McCaffrey

Resverlogix Corp. is an advanced-stage biotechnology company that focuses on developing therapies for medical conditions with significant unmet needs. The company's primary asset is apabetalone (RVX-208), a specialized small molecule bro...